781 related articles for article (PubMed ID: 30053671)
1. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
[TBL] [Abstract][Full Text] [Related]
2. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Turner NC; Finn RS; Martin M; Im SA; DeMichele A; Ettl J; Diéras V; Moulder S; Lipatov O; Colleoni M; Cristofanilli M; Lu DR; Mori A; Giorgetti C; Iyer S; Bartlett CH; Gelmon KA
Ann Oncol; 2018 Mar; 29(3):669-680. PubMed ID: 29342248
[TBL] [Abstract][Full Text] [Related]
3. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Diéras V; Rugo HS; Schnell P; Gelmon K; Cristofanilli M; Loi S; Colleoni M; Lu DR; Mori A; Gauthier E; Huang Bartlett C; Slamon DJ; Turner NC; Finn RS
J Natl Cancer Inst; 2019 Apr; 111(4):419-430. PubMed ID: 30032196
[TBL] [Abstract][Full Text] [Related]
4. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Ohtani S; Shimizu C; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2021 Mar; 28(2):335-345. PubMed ID: 33085032
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
6. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
7. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
9. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Masuda N; Inoue K; Nakamura R; Rai Y; Mukai H; Ohno S; Hara F; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Huang X; Iwata H
Int J Clin Oncol; 2019 Mar; 24(3):262-273. PubMed ID: 30392115
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
12. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS; Finn RS; Diéras V; Ettl J; Lipatov O; Joy AA; Harbeck N; Castrellon A; Iyer S; Lu DR; Mori A; Gauthier ER; Bartlett CH; Gelmon KA; Slamon DJ
Breast Cancer Res Treat; 2019 Apr; 174(3):719-729. PubMed ID: 30632023
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
17. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Finn RS; Boer K; Bondarenko I; Patel R; Pinter T; Schmidt M; Shparyk YV; Thummala A; Voitko N; Bananis E; McRoy L; Wilner K; Huang X; Kim S; Slamon DJ; Ettl J
Breast Cancer Res Treat; 2020 Sep; 183(2):419-428. PubMed ID: 32683565
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Mukai H; Shimizu C; Masuda N; Ohtani S; Ohno S; Takahashi M; Yamamoto Y; Nishimura R; Sato N; Ohsumi S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Lu DR; Toi M
Int J Clin Oncol; 2019 Mar; 24(3):274-287. PubMed ID: 30515674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
